Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK Consumer: Looking for rhythm - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 25, 2004

    GSK Consumer: Looking for rhythm

    Performance summary
    GSK Consumer Healthcare has reported 3% revenue growth during the third quarter ended September 2004. The company margins have improved significantly, thereby resulting in a 37% bottomline growth during the quarter. For the nine months ended September 2004, GSK has reported almost 8% revenue and around 7% bottomline growth.

    (Rs m) 3QCY03 3QCY04 Change 9mCY03 9mCY04 Change
    Net sales 2,281 2,350 3.0% 6,074 6,552 7.9%
    Expenditure 1,986 1,928 -2.9% 5,048 5,446 7.9%
    Operating Profit (EBDITA) 295 422 43.2% 1,026 1,106 7.8%
    EBDITA margin (%) 12.9% 17.9%   16.9% 16.9%  
    Other income 47 30 -36.1% 149 104 -30.2%
    Interest (1) (3) 85.7% 5 -20 -476.9%
    Depreciation 87 90 4.2% 269 268 -0.2%
    Profit before Tax 257 364 42.0% 900 961 6.7%
    Tax 87 138 58.4% 309 354 14.6%
    Extraordinary income/(expense) (5) - - (22) - -
    Profit after Tax 165 226 37.3% 569 607 6.6%
    Net profit margin (%) 7.2% 9.6%   9.4% 9.3%  
    No. of Shares (m) 45.4 45.4   45.4 45.4  
    Diluted Earnings per share (Rs)* 14.5 19.9   16.7 17.8  
    Price to earnings ratio (x)         14.1  
    *(annualised), CY = Calendar Year            

    What is the company’s business?
    GSK Consumer dominates the Rs 13 bn Indian malted beverage market with a significant 65% share (volume terms). Its white beverage brand ‘Horlicks’ has led to the market growth of this sector in India and contributes around 80% to the company’s revenues. The company’s other brands include ‘Boost’, ‘Viva’ and ‘Maltova’. The company also earns 4-5% fees by marketing products for SmithKline Beecham Asia Pvt. Ltd, the parent’s 100% subsidiary. The subsidiary has well known brands like ‘Aquafresh’ in oral care segment, ‘Eno’ and ‘Crocin’ in OTC portfolio. It recently also took up marketing of ‘Iodex’ for GSK Pharma.

    What has driven performance in 3QCY05?
    Sales:  The company is still unable to find a rhythm in its revenue trend. It still seems to be struggling and is yet to stabilise. Its revenue trend has been very volatile over the last seven quarters (see chart). GSK Consumer has provided no indication of how the malted beverage segment is growing, but we believe that the segment growth has slowed from its earlier average of 10% plus rate over the past decade.

    Operating margins:  One of the key reasons for the company reporting strong bottomline growth is the significant improvement in operating margins (up 5% YoY). This has come about as a result of a dip in advertising expenses as a percentage of sales, as well as its raw material costs. Also, the third quarter of last year was abnormally bad for the company, thus showing a higher base improvement this year. During the nine month period however, GSK's margins have remained stable.

    Cost break-up
    as a % of net sales 3QCY03 3QCY04 9mCY03 9mCY04
    Stock 3.3% 1.5% -0.9% 1.0%
    RM 34.5% 32.4% 36.0% 35.0%
    Finished goods 1.2% 1.3% 1.0% 1.0%
    Staff cost 10.0% 10.2% 10.5% 10.8%
    Advertising 14.4% 12.5% 11.5% 11.0%
    Other exps. 22.1% 23.0% 23.3% 23.2%
    Patent and trademark 1.1% 0.5% 1.2% 0.5%
    Def. Rev. exps. 0.5% 0.5% 0.6% 0.6%
    Total 87.1% 82.1% 83.1% 83.1%

    What to expect?
    The management has declared a second interim dividend of Rs 3.7 per share, taking the total interim dividend for 2004 to Rs 7 per share. The stock is trading at Rs 252, reflecting a P/E of 14.1 times annualised 9mCY04 earnings and market cap to sales of 1.3x. GSK Consumer has no doubt made some progress in reversing the decline in topline over the past few quarters. However, market conditions continue to be difficult for this single product company. A full fledged recovery in the company's fortunes still seems some time away and therefore, we view the company cautiously.



    Equitymaster requests your view! Post a comment on "GSK Consumer: Looking for rhythm". Click here!


    More Views on News

    GSK Consumer: On the Recovery Path (Quarterly Results Update - Detailed)

    Jun 20, 2017

    While GSK consumer reported muted revenue growth, volumes are seen to be recovering.

    GSK Consumer: Price Hike Hurts Volumes (Quarterly Results Update - Detailed)

    Nov 30, 2016

    GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.

    GSK Consumer: Slowdown in demand impacts sales (Quarterly Results Update - Detailed)

    Oct 5, 2016

    GSK Consumer Healthcare has announced the first quarter results of the financial year 2016-2017 (1QFY17). The company's sales declined by 1.4% YoY while net profit rose by 2.9% YoY during the quarter.

    GSK Consumer: A Forgetful Year (Quarterly Results Update - Detailed)

    Jun 1, 2016

    GSK Consumer Healthcare announced its results for the quarter and year ended March 2016. During the quarter, sales and profit came in lower by 9% YoY and 8% YoY respectively.

    GSK Consumer: Feeling the Growth Pressures? (Quarterly Results Update - Detailed)

    Feb 15, 2016

    GSK Consumer Healthcare announced its results for the quarter ended December 2015. While revenues were up by 2% YoY, profits were higher by 37% YoY.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 03:18 PM


    • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Financial Information With Charts